Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°¡Åä¿¡ À¯¹ßÇÑ ¼ö¼ú ÈÄ ¹ÝÈç¿¡ ´ëÇÑ ¿ªµ¿Àû Á¶¿µ Áõ°­ ÀÚ±â°ø¸í¿µ»ó Analysis of Signal Intensity Curve on Dynamic Contrast-Enhanced MR Imaging of Postoperative Scars in Rabbits:Comparison of Gadopentetate Dimeglumine and 24-gadolinium-tetraazacy-clododecanetetraacetic acid (DOTA)-dendrimer

´ëÇѹæ»ç¼±ÀÇÇÐȸÁö 2001³â 44±Ç 6È£ p.733 ~ 741
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÁØ¿ì:Lee Joon-Woo ¹®¿ì°æ:Moon Woo-Kyung/Àå±âÇö:Chang Kee-Hyun/±è¼öÁ¤:Kim Soo-Jeoung/±èÁ¾È¿:Kim Jong-Hyo/±èÅÂÁ¤:Kim Tae-Jeong/ÃÖÁØÀÏ:Choi Joon-Il/±è¼¼Çü:Kim Se-Hyung/±ÇÁ¾¿ø:Kwon Chong-Won/ÃÖº¸À±:Choi Bo-Yoon/±èȿö:Kim Hyo-Cheol/:Weinmann Hanns-Joachim

Abstract

¸ñÀû:°¡Åä¿¡¼­ ½ÇÇèÀûÀ¸·Î À¯¹ßÇÑ ¼ö¼úÈÄ ¹ÝÈç¿¡ ´ëÇØ 24-gadolinium-tetraazacyclododecane tetraacetic acid (DOTA)-dendrimer (Gadomer-17;Schering,Berlin,Germany)°ú gadopentetate dimeglumine (Magnevist; Schering,Berlin,Germany)¸¦ ÀÌ¿ëÇÑ ¿ªµ¿Àû Á¶¿µÁõ°­ ÀÚ±â°ø¸í¿µ»ó¿¡¼­ÀÇ Á¶¿µ Áõ°­ ÇàŸ¦ ºñ±³ÇØ º¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó°ú ¹æ¹ý:12 ¸¶¸®ÀÇ °¡Åä¿¡ ÇÑÂÊ ´Ù¸®¿¡ ¼ö¼úÀû ¹æ¹ýÀ¸·Î ¹ÝÈçÀ» ¸¸µç ÈÄ 24½Ã°£ °£°ÝÀ¸·Î µÎ °¡Áö Á¶¿µÁ¦ÀÎ Gadomer-17°ú gadopentetate dimeglumine¸¦ ÀÌ¿ëÇÏ¿© Á¶¿µÁ¦ ÁÖÀÔ ÈÄ 1,2,3,4,5,10,15,20,25,30ºÐ¿¡ ¿µ»óÀ» ¾ò´Â ¿ªµ¿Àû ÀÚ±â°ø¸í¿µ»óÀ» ½ÃÇàÇÏ¿´´Ù.ÇÑ´Þ Â° ¿­ ¸¶¸®,µÎ´Þ ° ¿©´ü ¸¶¸®,¼¼´Þ ° ³× ¸¶¸®,ÃÑ 22 ¹øÀÇ ½ÇÇèÀ» ½ÃÇàÇÏ¿´À¸¸ç,°¢ ½Ã°£´ç Á¶¿µºñ¸¦ ÀÌ¿ëÇØ ±×·¡ÇÁ¸¦ ±×¸° ÈÄ,°¢ ½Ã°£ ´ç Á¶¿µºñ,ÃÖ´ëÁ¶¿µºñ,°æ»ç,Á¶¿µ °î¼±ÀÇ ¸ð¾ç µîÀ» ºÐ¼®ÇÏ¿´´Ù.

°á°ú:Gadomer-17À» ÀÌ¿ëÇÑ ¿ªµ¿Àû Àڱ⠰ø¸í ¿µ»ó¿¡¼­ °¢ ½Ã°£ ´ç Á¶¿µºñ´Â ¸ðµç ½Ã°£´ë¿¡¼­ gadopentetate dimeglumine ¿¡ ºñÇؼ­ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ³·¾Ò´Ù (p<0.05).ÃÖ´ë Á¶¿µºñµµ Gadomer-17ÀÇ °æ¿ì gadopentetate dimeglumine ¿¡ ºñÇؼ­ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ³·¾Ò´Ù (1.29 ¡¾0.15 vs 1.61 ¡¾0.31,p<0.01).Gadomer-17ÀÇ °æ¿ì °æ»çºñ´Â 2.99%/min ¡¾2.72¿´°í,gadopentetate dimeglumine ÀÇ °æ¿ì´Â 8.99%/min ¡¾7.32 ¿´´Ù (p<0.01). Gadomer-17ÀÇ °æ¿ì¿¡´Â ´ëºÎºÐ plateau ¾ç»ó (90.9%)ÀÇ Á¶¿µ Áõ°­ °î¼± ¸ð¾çÀ̾úÀ¸³ª gadopentetate dimeglumineÀÇ °æ¿ì¿¡´Â plateau ¾ç»ó°ú washout ¾ç»óÀÌ ¹Ý¹Ý¾¿À̾ú´Ù.µÎ Á¶¿µÁ¦ °£¿¡ ¿ªµ¿Àû ÀÚ±â°ø¸í ¿µ»ó¿¡¼­ÀÇ Á¶¿µºñÀÇ Â÷ÀÌ´Â 1 °³¿ù° ¹ÝÈç¿¡¼­ °¡Àå ÇöÀúÇÏ¿´´Ù.

°á·Ð:Gadomer-17À» ÀÌ¿ëÇÑ °æ¿ì´Â ¼ö¼ú ÈÄ ¹ÝÈç¿¡ ´ëÇÑ ¿ªµ¿Àû ÀÚ±â°ø¸í¿µ»ó¿¡¼­ gadopentetate dimeglumine º¸´Ù Á¶¿µ Á¤µµ°¡ ¾àÇϸç ÃÖ´ëÄ¡°¡ ³·°í º¸´Ù ´Ê°Ô ÃÖ´ëÄ¡¿¡ µµ´ÞÇϸç ÁÖ·Î plateau ¾ç»óÀÌÁö¸¸ gadopentetate dimeglumineÀÇ °æ¿ì¿¡´Â º¸´Ù Á¶¿µ Á¤µµ°¡ °­Çϸç washout À̳ª plateau ¾ç»óÀ̾ú´Ù.

Purpose: To compare the enhancement patterns of 24-gadolinium-tetrazacyclodode-cane tetracetic acid (DOTA)-dendrimer (Gadomer-17) with those of gadopentetate dimeglumine (Magnevist) in postoperative scars in rabbits.

Materials and Methods: Twelve rabbit thighs with experimentally induced postopera-tive scars underwent dynamic contrast-enhanced MR imaging with both Gadomer-17 and gadopentetate dimeglumine at a 24-hr interval at one (n = 10), two (n = 8) and three months (n=4) after scar induction. The enhancement and the ratios of lesions at each time point, peak enhancement ratios, and the slope and shape of curves were as-sessed.

Results: At all time points, enhancement ratios were significantly lower after the injection of Gadomer-17 than with gadopentetate dimeglumine (p<0.05). Peak enhance-ment ratios were significantly lower with Gadomer-17 (1.29 ¡¾0.15) than with gadopentetate dimeglumine (1.61 ¡¾0.31) (p<0.01). The slope values were 2.99%/min ¡¾2.72 after Gadomer-17 injection and 8.99%/min ¡¾7.32 after gadopentetate dimeglumine injection (p<0.01). The enhancement ratio curves showed mostly the plateau pattern with Gadomer-17 (90.9%), while for gadopentetate dimeglumine, the curve pattern was either plateau (50%) or washout (50%). Difference in enhancement char-acteristics between the two contrast agents were most pronounced for one-month scars.

Conclusion: With Gadomer-17, weaker enhancement and the plateau pattern were found in postoperative scars, whereas stronger enhancement and either washout or the plateau pattern were found with gadopentetate dimeglumine.

Å°¿öµå

Magnetic resonance (MR), experimental studies; Magnetic resonance (MR), contrast enhancement; Animals;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS